(Q43824475)

27 November 2017

title

Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy (English)

1 reference

27 November 2017

B M Chen

1

1 reference

27 November 2017

T L Cheng

series ordinal

2

1 reference

27 November 2017

S C Tzou

series ordinal

3

1 reference

27 November 2017

S R Roffler

series ordinal

4

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

International Journal of Cancer

27 November 2017

published in

1 reference

27 November 2017

volume

94

1 reference

27 November 2017

issue

6

1 reference

27 November 2017

page(s)

850-858

1 reference

A cytotoxic agent can be generated selectively at cancer sites

27 November 2017

cites work

1 reference

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

21 January 2018

1 reference

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

21 January 2018

1 reference

Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.

21 January 2018

1 reference

In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats

21 January 2018

1 reference

Prevention of diabetes in BioBreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells

21 January 2018

1 reference

Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines

21 January 2018

1 reference

Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents

21 January 2018

1 reference

Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo

21 January 2018

1 reference

Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression

21 January 2018

1 reference

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

21 January 2018

1 reference

Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect

21 January 2018

1 reference

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

21 January 2018

1 reference

Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses

21 January 2018

1 reference

Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1.

21 January 2018

1 reference

Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity

21 January 2018

1 reference

Combination gene therapy for liver metastasis of colon carcinoma in vivo

21 January 2018

1 reference

Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines

21 January 2018

1 reference

Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer

21 January 2018

1 reference

Clinical trials of antibody therapy

21 January 2018

1 reference

Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice

21 January 2018

1 reference

Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation

21 January 2018

1 reference

Clinical evaluation of two weekly dose schedules of 'IC-140'. 4-N, N-bis (2-Chloroethyl) amino phenyl N (P-carboxyphenyl) carbamate, in the treatmentment of solid tumors 1,2

21 January 2018

1 reference

Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate

21 January 2018

1 reference

Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats

21 January 2018

1 reference

MRC OX-19: a monoclonal antibody that labels rat T lymphocytes and augments in vitro proliferative responses

21 January 2018

1 reference

Molecular nature of the W3/25 and MRC OX-8 marker antigens for rat T lymphocytes: comparisons with mouse and human antigens

21 January 2018

1 reference

The JAM test. A simple assay for DNA fragmentation and cell death

21 January 2018

1 reference

Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard

21 January 2018

1 reference

The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells

21 January 2018

1 reference

Characterization of an antineoplastic glucuronide prodrug

21 January 2018

1 reference

Immunocytokines: a promising approach to cancer immunotherapy

21 January 2018

1 reference

Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.1550

1 reference

27 November 2017

1 reference